Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuhiro Yuki

Showing results (21-30 of 232) with videos related to

Pageof 24
Sort By:
Scientific Reports|July 22, 2015
Streptococcal IdeS: therapeutic potential for Guillain-Barré syndromeRyo Takahashi, Nobuhiro Yuki
Nature Reviews. Neurology|June 22, 2011
Peripheral neuropathies: clinical prognostic scales in Guillain-Barré syndromeNortina Shahrizaila, Nobuhiro Yuki
Journal of Neurology, Neurosurgery, and Psychiatry|May 10, 2011
Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain-Barre syndrome?Nobuhiro Yuki, Nortina Shahrizaila
Expert Review of Neurotherapeutics|June 6, 2009
Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypesAntonino Uncini, Nobuhiro Yuki
Internal Medicine (Tokyo, Japan)|April 23, 2003
Antibodies to GM2 ganglioside in neurological disordersMasaaki Odaka, Nobuhiro Yuki
The Lancet. Neurology|November 16, 2013
Axonal Guillain-Barré syndrome: concepts and controversiesSatoshi Kuwabara, Nobuhiro Yuki
Expert Opinion on Pharmacotherapy|April 9, 2011
The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of actionNortina Shahrizaila, Nobuhiro Yuki
Journal of the Peripheral Nervous System : JPNS|November 29, 2007
Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiologyNobuhiro Yuki, Satoshi Kuwabara
Rinsho Shinkeigaku = Clinical Neurology|November 2, 2004
[Intravenous immunoglobulin therapy for Guillain-Barré syndrome in Japan: changes in treatment after its inclusion in health insurance coverage]Yukihiro Nishimoto, Nobuhiro Yuki
Current Opinion in Neurology|September 13, 2005
Ganglioside mimicry as a cause of Guillain-Barré syndromeNobuhiro Yuki, Masaaki Odaka
Pageof 24

Showing results (21-30 of 232) with videos related to

Sort By:
Pageof 24
Scientific Reports|July 22, 2015
Streptococcal IdeS: therapeutic potential for Guillain-Barré syndromeRyo Takahashi, Nobuhiro Yuki
Nature Reviews. Neurology|June 22, 2011
Peripheral neuropathies: clinical prognostic scales in Guillain-Barré syndromeNortina Shahrizaila, Nobuhiro Yuki
Journal of Neurology, Neurosurgery, and Psychiatry|May 10, 2011
Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain-Barre syndrome?Nobuhiro Yuki, Nortina Shahrizaila
Expert Review of Neurotherapeutics|June 6, 2009
Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypesAntonino Uncini, Nobuhiro Yuki
Internal Medicine (Tokyo, Japan)|April 23, 2003
Antibodies to GM2 ganglioside in neurological disordersMasaaki Odaka, Nobuhiro Yuki
The Lancet. Neurology|November 16, 2013
Axonal Guillain-Barré syndrome: concepts and controversiesSatoshi Kuwabara, Nobuhiro Yuki
Expert Opinion on Pharmacotherapy|April 9, 2011
The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of actionNortina Shahrizaila, Nobuhiro Yuki
Journal of the Peripheral Nervous System : JPNS|November 29, 2007
Axonal Guillain-Barré syndrome: carbohydrate mimicry and pathophysiologyNobuhiro Yuki, Satoshi Kuwabara
Rinsho Shinkeigaku = Clinical Neurology|November 2, 2004
[Intravenous immunoglobulin therapy for Guillain-Barré syndrome in Japan: changes in treatment after its inclusion in health insurance coverage]Yukihiro Nishimoto, Nobuhiro Yuki
Current Opinion in Neurology|September 13, 2005
Ganglioside mimicry as a cause of Guillain-Barré syndromeNobuhiro Yuki, Masaaki Odaka
Pageof 24